Found 21 matching trials
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) PHASE2 This study is a prospective, open-label, multicenter study in previously un...
Show More Location
The Affiliated Hospital of Xuzhou Medical University
Learn More & Join Trial
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma PHASE2 This is a single-arm, prospective clinical study to evaluate the efficacy a...
Show More Location
Second Affiliated Hospital, School of Medicine, Zhejiang University
Learn More & Join Trial
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment PHASE3 This multicenter, open-label, randomized controlled trial aims to evaluate ...
Show More Learn More & Join Trial
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma PHASE3 B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Altho...
Show More Location
Shandong Provincial Hospital
Learn More & Join Trial
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL PHASE1 This is a single arm, single center, open label pilot study of Orelabrutini...
Show More Location
Department of Hematology, Huashan Hospital, Fudan University
Learn More & Join Trial
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma PHASE2 Assess the preliminary efficacy and safety of orelabrutinib in combination ...
Show More Location
Second Affiliated Hospital, School of Medicine, Zhejiang University
Learn More & Join Trial
Clinical Study of OR for Second-line Treatment of Refractory MZL PHASE4 The goal of this clinical trial is to test the overall response rate of Ore...
Show More Location
The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital
Learn More & Join Trial
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL PHASE2 This prospective, single-arm, multicenter clinical study aims to enroll 30 ...
Show More Location
Affiliated hospital of Nantong University
Learn More & Join Trial
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL PHASE2 This is a three-arm, multicenter, randomized controlled trial. Eligible par...
Show More Location
Peking University Third Hospital
Learn More & Join Trial
First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) PHASE2 Exploring the efficacy and safety of first-line treatment of primary centra...
Show More Location
The First Affiliated Hospital of Ningbo University
Learn More & Join Trial